title: OP002. Impact of the NO-donor pentaerythrithyltetranitrate on perinatal outcome in high-risk pregnancies: A prospective randomized double blinded pilot study.
abstract: OBJECTIVE
  To evaluate the effectiveness of the oral NO-donor PETN in secondary prevention of intrauterine growth restriction (IUGR), preterm birth and preeclampsia in high risk pregnancies.
  
  
  METHODS
  111 women presenting with abnormal placental perfusion (bilateral notch or mean RI>0.7) at 19-24weeks of gestation were included in a prospective, randomized, placebo-controlled, double-blinded study. Primary endpoint was IUGR and/or perinatal death, secondary endpoints were preterm birth, preeclampsia and placental abruption.
  
  
  RESULTS
  54 women received PETN and 57 placebo. PETN significantly decreased the risk of IUGR and/or perinatal death (adjusted RR 0.623 [95% - CI: 0.395-0.983]). Preterm birth before 32weeks was reduced (adjusted RR 0.359 [95% - CI 0.123-1.054]) and no placental abruption occurred in the PETN, but 5 in the placebo group. There was no reduction of preeclampsia.
  
  
  CONCLUSIONS
  Significant reduction of adverse pregnancy outcome might be possible in pregnancies exhibiting abnormal placentation using PETN.
authors.forename: Schlembach
authors.initials: S
authors.lastname: Dietmar
authors.forename: Groten
authors.initials: G
authors.lastname: Tanja
authors.forename: Lehmann
authors.initials: L
authors.lastname: Thomas
authors.forename: Schneider
authors.initials: S
authors.lastname: Uwe
authors.forename: Schleussner
authors.initials: S
authors.lastname: Ekkehard